Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial.

ABSTRACT:

Background

Although, doxycycline use is associated with improved outcomes in amyloidosis in retrospective studies, evidence from clinical trials is limited.

Methods

This phase 2 trial of doxycycline (clinicaltrials.gov: NCT02207556) in newly diagnosed light chain (AL) amyloidosis enrolled 25 patients with systemic AL amyloidosis on treatment with doxycycline for 1 year along with chemotherapy. Outcomes of interest included mortality, organ response, and hematologic response rates at 1 year.

Findings

The median age was 62 years, 64% were male, and 68% had the AL lambda subtype. Patients had Mayo 2012 stage 3 in 24% and stage 4 in 28%. Cardiac involvement was present in 60% of patients, renal involvement in 72%, and 60% patients had 3 or more organs involved. Target org

SUBMITTER: D'Souza A 

PROVIDER: S-EPMC7280748 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature